^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MCL1 underexpression

    i
    Other names: MCL1, MCL1 Apoptosis Regulator BCL2 Family Member, Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1, Myeloid Cell Leukemia Sequence 1 (BCL2-Related), MCL1 BCL2 Family Apoptosis Regulator, Bcl-2-Related Protein EAT/Mcl1, Myeloid Cell Leukemia 1, Bcl-2-Like Protein 3, Bcl2-L-3, Mcl1/EAT, BCL2L3, BCL2 Family Apoptosis Regulator, Myeloid Cell Leukemia ES, MCL1-ES, MCL1L, MCL1S, Mcl-1, EAT, TM
    Entrez ID:
    4170
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells. (PubMed, Blood Adv)
    By contrast, there was less impact on circulating T cells and natural killer (NK) cells, with no changes in their subset composition, transcriptome or function following venetoclax treatment. Our data indicate that venetoclax has minimal impact on circulating T or NK cells, supporting the rationale of combining this BH3 mimetic drug with cancer immunotherapies for more durable anti-tumour responses.
    Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1)
    |
    MCL1 expression • MCL1 underexpression
    |
    Venclexta (venetoclax)
    over1year
    Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. (PubMed, Cell Death Dis)
    Inhibition of immunoproteasome with ONX-0914 suppressed activity of immunoproteasome and synergized with venetoclax against primary CLL cells. Inhibition of p38 MAPK or immunoproteasome triggered apoptosis in CLL cells and overcame the resistance to venetoclax of MEC-1 VER cells and venetoclax-insensitive primary CLL cells. In conclusion, the p38 MAPK pathway and immunoproteasome represent novel targets to combat venetoclax resistance in CLL.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • MCL1 (Myeloid cell leukemia 1) • IFNG (Interferon, gamma) • CD40LG (CD40 ligand)
    |
    CD19 positive • MCL1 expression • MCL1 underexpression • BAX expression • BAX underexpression
    |
    Venclexta (venetoclax) • ONX 0914